International Cancer Screening Network (ICSN)
Overview
The International Cancer Screening Network (ICSN), organized by the Center for Global Health (CGH), is an international community of cancer screening experts that promotes collaborative research and implementation of evidence-based cancer screening.
Impact
ICSN convenes experts to develop the evidence base for effective practices in cancer screening and advises settings on how to improve their own national cancer screening programs. It does this by
- organizing biennial conferences and working groups for screening practitioners (researchers, evaluators, implementers, and screening program staff) to exchange data and experiences
- connecting 800+ participants from 69 countries with active screening programs for breast, cervical, and colorectal cancers
- sharing evidence-based implementation efforts built on research, monitoring, and evaluation
- advising on study designs to evaluate the process and effectiveness of cancer screening programs
- providing education about cancer screening, from basics to advanced and emerging concepts
- coordinating scientific studies and publishing collaborative papers
- as of 2020, studying the effects of the COVID-19 pandemic on cancer screening and how programs have adapted around the world
How to Connect
ICSN is open to any participants who are interested in cancer screening. In-person meetings usually happen every two years and information about venue, registration costs, and program are disseminated within the network. There are no membership dues.
Visit the ICSN website for more information about the network and preparations for ICSN 2025, June 18-20, in Aarhus, Denmark.
Collaborators
ICSN was founded in 1988 under the leadership of Professor Sam Shapiro. NCI has supported the evolution and sustainment of ICSN from the inception of the network, with CGH helping coordinate since 2015.
Chair: Miriam Elfström, Ph.D., Center for Cervical Cancer Elimination, Karolinska Institute, Sweden
Chair-Elect: Christine Campbell, Ph.D., Usher Institute, University of Edinburgh, UK
The steering committee includes members from Addis Ababa University; American Cancer Society; AOU Città della Salute e della Scienza – CPO Piemonte, Italy; BC Cancer Research Institute, Canada; Institute of Clinical Medicine, Denmark; Israel Institute of Technology ; Karolinska Institute; National Screening Centre, Czech Republic; Radboud University Medical Center; Randers Regional Hospital, Denmark; Telstra Health, Australia; University Hospital Città della Salute e della Scienza, Italy; University of Campinas; University of Edinburgh; and the University of Glasgow.